Abnova (Taiwan) Corporation — Investor Relations & Filings
Abnova Corporation is a global leader in the high-throughput production of antibodies and recombinant proteins. By integrating industrial-scale manufacturing with IT-driven management systems, the company maintains one of the world's largest catalogs of biological reagents. Its core offerings encompass gene synthesis, cytogenetics, peptide services, and protein expression. Abnova provides comprehensive solutions for life science research, including custom antibody production, scale-up, and humanization. Recent technological expansions include the RNAutomation™ mRNA service, NanoAb™ services, and nanoCAR-T mRNA solutions. The company supports academic and industrial researchers across multidisciplinary fields with integrated assay development and advanced bioreagent tools.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529F02.pdf | 2026-04-27 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529F13.pdf | 2026-04-27 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529FE2.pdf | 2026-04-27 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529FE1.pdf | 2026-04-27 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41460733 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41458395 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 37326076 | 115年年報及股東會資料 — 2026_4133_20260529F02.pdf | 2026-04-27 | Chinese | ||
| 37325954 | 115年年報及股東會資料 — 2026_4133_20260529F13.pdf | 2026-04-27 | Chinese | ||
| 37326464 | 115年年報及股東會資料 — 2026_4133_20260529FE2.pdf | 2026-04-27 | Chinese | ||
| 37274664 | 115年年報及股東會資料 — 2026_4133_20260529FE1.pdf | 2026-04-27 | English | ||
| 37274646 | 115年年報及股東會資料 — 2026_4133_20260529F01.pdf | 2026-04-27 | Chinese | ||
| 33993210 | 115年3月背書保證與資金貸與 | 2026-04-10 | Chinese | ||
| 33991866 | 115年3月營業收入 | 2026-04-10 | Chinese | ||
| 34543552 | 115年03月內部人持股異動(事後) | 2026-04-02 | Chinese | ||
| 34543547 | 115年03月董事會成員及持股 | 2026-04-02 | Chinese | ||
| 34543557 | 115年04月僑外投資持股 | 2026-04-01 | Chinese | ||
| 34543564 | 115年2月營業收入 | 2026-03-10 | Chinese | ||
| 34543561 | 115年2月背書保證與資金貸與 | 2026-03-10 | Chinese | ||
| 34543571 | 115年02月董事會成員及持股 | 2026-03-03 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Vaxil Bio Ltd.
Uses a proprietary Signal Peptide platform to develop immun…
|
VXL | CA | Professional, scientific and te… |
|
Vcanbio Cell & Gene Engineering Corp., Ltd
Focuses on stem cell bio-banking, genetic testing, and cell…
|
600645 | CN | Professional, scientific and te… |
|
VECTUS BIOSYSTEMS LIMITED
Develops therapeutics to reverse fibrosis and hypertension …
|
VBS | AU | Professional, scientific and te… |
|
Veradermics, Inc
Clinical-stage biopharmaceutical company developing medical…
|
MANE | US | Professional, scientific and te… |
|
Vera Therapeutics, Inc.
Clinical-stage biotech developing treatments for immunologi…
|
VERA | US | Professional, scientific and te… |
|
Veritas In Silico Inc.
A drug discovery company developing mRNA-targeting therapeu…
|
130A | JP | Professional, scientific and te… |
|
ViGenCell Inc.
Develops immune cell therapies to treat cancer and other in…
|
308080 | KR | Professional, scientific and te… |
|
Viking Therapeutics, Inc.
Clinical-stage biopharma developing therapies for metabolic…
|
VKTX | US | Professional, scientific and te… |
|
Vimta Labs Ltd.
Contract research and testing organization for life science…
|
VIMTALABS | IN | Professional, scientific and te… |
|
Vinext S.p.A.
Develops sustainable technology for the oenology and agri-f…
|
VNXT | IT | Professional, scientific and te… |
Abnova (Taiwan) Corporation via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52384/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52384 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52384 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52384 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52384}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Abnova (Taiwan) Corporation (id: 52384)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.